STOCK TITAN
  1. Home
  2. News
  3. AIMI

Aim Immunotech Stock Price, News & Analysis

AIMI NYSE

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIMI), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aim Immunotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aim Immunotech's position in the market.

News

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) announced a presentation at the U.S.-Poland Science and Technology Symposium 2025 featuring Dr. Pawel Kalinski's discussion on the company's drug Ampligen. The presentation, held from June 17-20, 2025, focused on the potential of private-public partnerships in developing oncology treatments.

Dr. Kalinski, a senior investigator for multiple Ampligen oncology studies, highlighted opportunities for expansion in the United States and Eastern European countries through initiatives like the Translational Research Cancer Centers Consortium. CEO Thomas K. Equels will pursue potential clinical partnerships and licensing agreements in Europe, particularly in Poland, at the upcoming Marie Sklodowska-Curie Symposia in September 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements

Rhea-AI Summary
AIM ImmunoTech has received a warning notification from NYSE American due to noncompliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of negative $3.9 million as of March 31, 2025, and has experienced losses in the past five fiscal years. NYSE American requires stockholders' equity of $4.0 million for companies with losses in three of four recent fiscal years, and $6.0 million for those with losses in five recent fiscal years. This follows a previous warning issued in December 2024. AIM has submitted a compliance plan that was accepted by NYSE American, giving the company until June 11, 2026, to meet requirements. The company's stock continues trading under symbol AIM, and the notice does not affect its business operations or SEC reporting requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

AIM ImmunoTech Resumes Trading on NYSE American

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) has announced the resumption of trading of its common stock on the NYSE American exchange effective June 17, 2025. The company's shares are trading under the ticker symbol 'AIM' with CUSIP number 00901B303. The resumption of trading on NYSE American, one of the major U.S. stock exchanges, marks an important milestone for the company's market presence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Rhea-AI Summary
AIM ImmunoTech has secured a significant U.S. patent (No. 12312376) for manufacturing therapeutic double-stranded RNA (dsRNA) products, including Ampligen, extending protection until 2041. This patent complements AIM's existing portfolio covering Ampligen's manufacture, composition, and therapeutic applications. The company's IP portfolio includes patents for treating cancer (expires 2039), Post-COVID fatigue (expires 2042), and endometriosis (expires 2040). Additionally, AIM holds multiple Orphan Drug Designations from FDA and EMA, providing 7-10 years of market exclusivity post-approval for conditions including Metastatic Melanoma, Renal Cell Carcinoma, Pancreatic Adenocarcinoma, Ebola Virus Disease, Chronic Fatigue Syndrome, and HIV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Rhea-AI Summary
AIM ImmunoTech (NYSE American: AIM) announced that NYSE Regulation has withdrawn its delisting determination and will lift the trading suspension of the company's common stock. The decision comes after the company's stock price rose above the minimum threshold required by Section 1003(f)(v) of the NYSE American Company Guide. Trading of AIM's common stock is set to resume on the NYSE American on Tuesday, June 17, 2025, under the symbol 'AIM' with CUSIP 00901B303. This development marks a significant turnaround for the company, ensuring its continued listing on a major exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Rhea-AI Summary
AIM ImmunoTech (NYSE: AIM) has announced a 1-for-100 reverse stock split effective June 12, 2025. The primary objective is to boost the company's per-share market price to regain compliance with NYSE American's Listing Qualifications. The split was approved by stockholders at a Special Meeting on April 30, 2025. Following the split, the company's OTC Pink ticker will temporarily change to AIMID for 20 trading days. Stockholders will receive cash for any fractional shares post-split. The company's common stock will maintain its $0.001 par value but will be assigned a new CUSIP number: 00901B303.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
stock split
News

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

Rhea-AI Summary
AIM ImmunoTech (NYSE: AIM) presented clinical trial data for its drug Ampligen at the Annual Meeting of the American Association of Immunologists. Dr. Pawel Kalinski's presentation highlighted Ampligen's unique two-level selectivity when combined with PD-1 blockade or chemotherapy. The drug demonstrated the ability to: 1. Selectively induce CTL-attracting chemokines without triggering counterproductive Treg-attracting chemokines 2. Preferentially activate cancer tissues over healthy tissues The research showed that Ampligen's selective impact on tumor microenvironment stems from its ability to avoid helicase-dependent activation of NFkB, differentiating it from poly-I:C and other TLR ligands.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.12%
Tags
none
-
News

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Rhea-AI Summary

AIM ImmunoTech (OTC Pink: AIMI), an immuno-pharma company specializing in therapeutics for cancers, immune disorders, and viral diseases including COVID-19, has announced its transition to trading under the ticker AIMI on the Pink Open Market effective April 07, 2025.

The company also confirmed its upcoming Special Meeting scheduled for April 30, 2025, where a reverse split proposal will be discussed. Shareholders can find detailed information in AIM's Definitive Proxy Statement filed on April 2, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Aim Immunotech (AIMI)?

The current stock price of Aim Immunotech (AIMI) is $0.0711 as of June 11, 2025.
Stock AIMI logo
Aim Immunotech

NYSE:AIMI

AIMI Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

AIMI Stock Data

67.20M